Immune-related adverse events of immune checkpoint inhibitors: a review

被引：43

作者：

Yin, Qinan ^{[1
,2
]}

Wu, Liuyun ^{[1
,2
]}

Han, Lizhu ^{[1
,2
]}

Zheng, Xingyue ^{[1
,2
]}

Tong, Rongsheng ^{[1
,2
]}

Li, Lian ^{[1
,2
]}

Bai, Lan ^{[1
,2
]}

Bian, Yuan ^{[1
,2
]}

机构：

[1] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sch Med, Dept Pharm, Chengdu, Peoples R China

[2] Univ Elect Sci & Technol China, Sch Med, Personalized Drug Therapy Key Lab Sichuan Prov, Chengdu, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷

关键词：

immune checkpoint inhibitors; immune-related adverse events; epidemiology; mechanism; management; PD-1/PD-L1; INHIBITORS; CANCER-IMMUNOTHERAPY; CLINICAL-TRIALS; DOUBLE-BLIND; OPEN-LABEL; T-CELLS; MELANOMA; TOCILIZUMAB; MYOCARDITIS; TOXICITY;

D O I：

10.3389/fimmu.2023.1167975

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.

引用

页数：17

共 50 条

[1] Immune-related adverse events of immune checkpoint inhibitors: a brief review
Myers, G.
[J]. CURRENT ONCOLOGY, 2018, 25 (05) : 342 - 347
[2] Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Ramos-Casals, Manuel
Siso-Almirall, Antoni
[J]. ANNALS OF INTERNAL MEDICINE, 2024, : ITC17 - ITC32
[3] Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, Manuel
Brahmer, Julie R.
Callahan, Margaret K.
Flores-Chavez, Alejandro
Keegan, Niamh
Khamashta, Munther A.
Lambotte, Olivier
Marlette, Xavier
Prat, Aleix
Suarez-Almazor, Maria E.
[J]. NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)
[4] Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals
Julie R. Brahmer
Margaret K. Callahan
Alejandra Flores-Chávez
Niamh Keegan
Munther A. Khamashta
Olivier Lambotte
Xavier Mariette
Aleix Prat
Maria E. Suárez-Almazor
[J]. Nature Reviews Disease Primers, 6
[5] Immune-related adverse events of checkpoint inhibitors
不详
[J]. Nature Reviews Disease Primers, 6 (1) : 39
[6] Immune-Related Adverse Events From Immune Checkpoint Inhibitors
Marrone, K. A.
Ying, W.
Naidoo, J.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 242 - 251
[7] Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann, Sandra M.
Perazella, Mark A.
[J]. KIDNEY INTERNATIONAL REPORTS, 2020, 5 (08): : 1139 - 1148
[8] Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Daphne Day
Aaron R. Hansen
[J]. BioDrugs, 2016, 30 : 571 - 584
[9] Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, Daphne
Hansen, Aaron R.
[J]. BIODRUGS, 2016, 30 (06) : 571 - 584
[10] Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Stelmachowska-Banas, Maria
Czajka-Oraniec, Izabella
[J]. ENDOCRINE CONNECTIONS, 2020, 9 (10): : R207 - R228

← 1 2 3 4 5 →